• The Korean Journal of Nuclear Medicine
• /
• v.3 no.1
• /
• pp.51-58
• /
• 1969

To clarify the hematologic effects of the radioiodine ($^{131}I$) in therapeutic doses ($5{\sim}10$ mCi) on the various thyroid patients, authors studied the peripheral blood pictures of 396 goitrous patients before and after radioiodine ($^{131}I$) administrations in the Isotope Clinic of Seoul National University Hospital. Among these 396 cases of goiters, we gave 5 to 10 mCi of radioiodine ($^{131}I$) with single or fractionated administrations. The blood pictures of peripheral blood were repeated after 3 months in 40 cases of 65 cases who had been treated with $^{131}I$. The blood pictures of non-treated thyroid patients were compared with that of normal Korean values to clarify any difference between normal and goiter. The blood pictures of hyperthyroid patients treated with $^{131}I$ therapy were compared with the blood pictures of non-treated thyroid patients. The results were as following: 1) The incidence according to type: Toxic diffuse goiter: 35.4% Nontoxic nodular goiter: 29.7% Euthyroid: 13.8% Nontoxic diffuse goiter: 12.6% Hypothyroidism: 4.3% Thyroiditis($\bar{s}$ subacute form): 1.8% Toxic nodular goiter: 1.4% Malignancy: 1.0% 2) Age incidence: The range of distribution was 11 to 71 years. The peak incidence was found in the 4th decade of life. $80.6{\sim}82.6%$ of those 396 cases were found among the 3rd, 4th and the 5th decades of life. 3) Sex incidence: Sex ratio of male:female was 1:7.8. 4) The most outstanding findings in peripheral blood before treatment were decreased erythrocyte count and hemoglobin value in all types of thyroid diseases, especially in. the cases of hypothyroidism and thyroiditis. Hook worm-infested patients showed no significant difference in erythrocytes and hemoglobin values from those of other hook worm free patients. 5) Total leukocytes count was within normal range. Differential count of W.B.C. showed increased percentile of lymphocyte in diffuse toxic goiter and thyroiditis. 6) 39 cases of diffuse goiter treated with $^{131}I$ toxic showed amelioration in the anemia and restoration to normal range of lymphocyte count in association with increased percentile of neutrophiles 3 months after administration, except a case of toxic nodular goiter. One can observe anemia in slight degree, and increased lymphocytes count in hypothyroidism. Therapeutic dose of radioiodine ($^{131}I$) does not result any residual effect on the hematopoietic function. Radioiodine ($^{131}I$) therapy resulted in improvement of thyroid function in association of amelioration of pevious abnormal blood pictures. 7) Authors did not observe any myxedema resulted from radioiodine therapy during the 3 months period in this study.

• The Korean Journal of Nuclear Medicine
• /
• v.35 no.6
• /
• pp.393-397
• /
• 2001

Surgery, radioiodine therapy, and thyroxine treatment represent established therapeutic measures of proven efficacy for the treatment of well-differentiated thyroid cancer. However, in some cases, dedifferentiation is noted and it makes tumors refractory to conventional treatment. Recently, retinoic acid redifferentiation therapy was evaluated in several in vitro and in vivo studios. We report a patient with papillary carcinoma in whom metastatic lesions became radioiodine negative on high-dose therapy. Redifferentiation therapy with retinoic acid induced radioiodine uptake in some of metastatic tissues. Side effects such as xerostomia and cheilosis were mild. We recommend retinoic acid redifferentiation therapy as an option for the treatment of thyroid cancer with negative radioiodine uptake after high-dose radioiodine therapy.

• 대한핵의학회:학술대회논문집
• /
• 1972.11a
• /
• pp.61.2-62
• /
• 1972

• 대한두경부종양학회:학술대회논문집
• /
• 2005.05a
• /
• pp.78-80
• /
• 2005

• Journal of radiological science and technology
• /
• v.31 no.1
• /
• pp.41-47
• /
• 2008

In order to better understand the effects of absorbed radioiodine upon Korean reference adult male, a mathematical phantom representation was contrived based on composite data of the physiology of Korean reference adult male. Using this, S-values of radioiodine($^{131}I$) per each organ were calculated. The calculated S-values were compared to the existing data described in the TM-8381 report of ORNLcalculated on the basis of an ICRP-23 reference male. The results indicated that S-values were higher for the phantom based on Korean reference adult male. The results of this study illustrate that, while the bio-chemical constitution of each source and target organ of the torso are important, the relative location of the organs and characteristics of the radionuclides also exert important influences.

• Journal of radiological science and technology
• /
• v.11 no.1
• /
• pp.63-69
• /
• 1988

In case of occuring the atomic energy accidents the proper medical treatments should be necessary. As the aim of the basic data for protective actions, the present studies were carried out to evaluate the decontamination of radioiodine by the administration of the antithyroid drugs (KI, NaI) and isotonic saline. Some recommended methods of decorporating radioiodine were investigated using 450, NIH-GP mice, each injected intraperitoneally with $1{\mu}Ci$ of $NaI^{131}$ as the internal contamination and treated with 2mg/0.2ml-saline of NaI and 2.6mg/0.2ml-saline of KI as the antithyroid drugs. Accordingly, effects of antithyroid drugs for internal contamination were: 1. Administration of NaI and KI caused to rapidly excrete internal radioiodine as the antithyroid drugs and decrease in whole body retention was reduced than in the saline group. 2. After internal contamination NaI and KI were to be administered for radioprotective effects as quickly as possible. 3. Decrease in body-retention made temporary shifts with enough fluids (water), however, as far as radioprotective effects is concerned, saline was not more significant than in the other group (NaI and KI). 4. Regarding to thyroid protective effects NaI, KI and saline were significant in effectively order.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.6
• /
• pp.2523-2527
• /
• 2014

Background: Serum thyroglobulin detection plays an essential role during the follow-up of thyroid cancer patients treated with total/near total thyroidectomy and radioiodine ablation. The aim of this retrospective study was to evaluate the relationship between stimulated serum thyroglobulin (Tg) level at the time of high dose $^{131}I$ ablation and risk of recurrence, using a three-level classification in patients with differentiated thyroid cancer (DTC) according to the ATA guidelines. Also we investigated the relationship between postoperative stimulated Tg at the time of ablation and DxWBS results at 8-10 months thereafter. Materials and Methods: Patients with radioiodine accumulation were regarded as scan positive (scan+). If there was no relevant pathological radioiodine accumulation or minimal local accumulation in the thyroid bed region, this were regarded as scan negative (scan-) at the time of DxWBS. We classified patients in 3 groups as low, intermediate and high risk group for assessment of risk of recurrence according to the revised ATA guidelines. Also, we divided patients into 3 groups based on the stimulated serum Tg levels at the time of $^{131}I$ ablation therapy. Groups 1-3 consisted of patients who had Tg levels of ${\leq}2ng/ml$, 2-10 ng/ml, and ${\geq}10ng/ml$, respectively. Results: A total of 221 consecutive patients were included. In the high risk group according to the ATA guideline, while 45.5% of demonstrated Scan(+) Tg(+), 27.3% of patients demonstrated Scan(-) Tg(-); in the intermediate group, the figures were 2.3% and 90.0% while in the low risk group, they were 0.6% and 96.4%. In 9 of 11 patients with metastases (81.8%), stimulated serum Tg level at the time of radioiodine ablation therapy was over 10, however in 1 patient (9.1%) it was <2ng/mL and in one patient it was 2-10ng/mL (p=0.005). Aggressive subtypes of DTC were found in 8 of 221 patients and serum Tg levels were ${\leq}2ng/ml$ in 4 of these 8. Conclusions: We conclude that TSH-stimulated serum thyroglobulin level at the time of ablation may not determine risk of recurrence. Therefore, DxWBS should be performed at 8-12 months after ablation therapy.

• The Korean Journal of Nuclear Medicine
• /
• v.34 no.4
• /
• pp.265-275
• /
• 2000

The thyroid gland is an interesting endocrine organ where a spectrum of tumors with different behavior arise. At one end of spectrum there is differentiated thyroid carcinoma (DTC) with excellent prognosis, whereas at the other end of the spectrum is anaplastic thyroid cancer which has universally poor outcome. Radioiodine (I-131) therapy has been in use for the treatment of thyroid diseases since 1946. It was introduced by Seidlin et al. 1) Although the use of I-131 has been vouge for a long time, its use in therapy for well differentiated thyroid cancer is still controversial 2). This is because, thyroid cancers (TC) are generally slow growing tumors, with low mortality and normal spans of survival. To record recurrence and mortality, long term follow up studies over a period of two to three decades are needed to establish definite conclusions on the acceptable mode of treatment The incidence of the disease being very low a large number of cases needed to establish a meaningful statistical data is lacking as most published reports feat with small series. Here again in the problem encountered are the differing protocols for treatment with I-131, the indications for treatment which may include or exclude ablation of residual thyroid tissue, cervical nodal and distal metastases. The dosage of I-131 used for ablation of residual thyroid tissue and metastatic disease also vary. The most reliable conclusion regarding I-131 treatment are obtained from studies reported on a large series of patients followed over a period of 2 decades or more from a single institute with a more or less unchanged protocol of management.

• The Korean Journal of Nuclear Medicine Technology
• /
• v.12 no.1
• /
• pp.119-122
• /
• 2008

Radioiodine (I-131) Therapy has been known one of the methods treated with hyperthyroidism and thyroid tumor, using a separate ward. This technique has been already used for several decades, and its clinical efficacy proven. Today, Radioiodine takes a form of capsule through continuous development, so, 30 odd domestic hospitals run about 63 separate wards. And, its demands would increase continuously; because of tending upwards the patients had thyroid cancer. However, various kinds of wastes originate from a procedure of radioiodine therapy. Especially, when their radioactivity exceed permissible level (4 Bq/$cm^2$) set by Nuclear laws of the Republic of Korea, it regards as radioactive wastes, then, managed separately from origination to the last disposal.

• The Korean Journal of Nuclear Medicine
• /
• v.36 no.1
• /
• pp.87-89
• /
• 2002

A 30 year-old female patient with papillary thyroid carcinoma received her fifth radioiodine ablation therapy after the subtotal thyroidectomy. The scan, which was peformed one week after the last therapy, revealed residual uptake in the thyroid bed and uptake in the anterior mediastinum suggesting metastasis. However, further evaluation of the thorax with chest CT and camera-based FDG PET confirmed normal thymus without metastatic focus. Occasionally thymus remains intact in adult and has avidity for I-131 and FDG. Therefore, normal thymus (instead of metastasis) should be considered in patients with well differentiated thyroid carcinoma and anterior mediastinal radioiodine uptake.